Searching…
Nov 7, 2025 · It also scored an approval 2 years later in 2023 for HR+/HER2– metastatic breast cancer treated with endocrine-based therapy and at least 2 additional systemic therapies, supported by the phase 3 TROPiCS...
Nov 7, 2025 · In the phase 3 ASCENT-07 trial, Trodelvy (sacituzumab govitecan-hziy) given as the first treatment after endocrine therapy did not improve progression-free survival compared with standard chemotherapy in...
Nov 7, 2025 · Participants in the trial had locally advanced, inoperable or HR+/HER2-negative metastatic breast cancer and had received prior endocrine therapy. The study enrolled 654 patients across nearly 30 ...
This phase II trial tests how well neratinib in combination with capecitabine works in treating patients with HER2-negative breast cancer that has spread from where it first started (primary site) to other places in t...
The results of the Phase III DESTINY-Breast04 trial of trastuzumab deruxtecan (T-DXd) are leading to a shift in both the classification and treatment of human epidermal growth factor receptor 2 (HER2)-negative metasta...
Jan 17, 2025 · Drug Approvals and Databases Resources for Information | Approved Drugs FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer
Nov 7, 2025 · The phase 3 ASCENT-07 trial did not meet its primary PFS end point with first-line sacituzumab govitecan in hormone receptor–positive, HER2-negative breast cancer.
Oct 21, 2023 · Sacituzumab govitecan demonstrated significant progression-free survival benefit over chemotherapy in the phase 3 TROPiCS-02 trial in patients with pretreated, endocrine-resistant hormone receptor-posit...
Aug 17, 2023 · HER2 mutations are targetable alterations in patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC). In the SUMMIT basket study, patients with HER2-mutant MBC received neratinib mo...
Dec 6, 2024 · Elfgen, C. & Bjelic-Radisic, V. Targeted therapy in HR+ HER2- metastatic breast cancer: current clinical trials and their implications for CDK4/6 inhibitor therapy and beyond treatment options.
